Product Description
berberine is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism.
Mechanisms of Action: AMPK Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | China | Hong Kong | India | Korea | New Zealand | Russia | Taiwan | United Arab Emirates | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Carmel Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Armenia, Sweden
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Mucositis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EP-1007 | P1 |
Not yet recruiting |
Mucositis |
2025-11-01 |
28% |